BRAIN Biotech AG has finalized a royalty monetization agreement with Royalty Pharma, securing up to €128.88 million for its investigational pharmaceutical compound, deucrictibant. The agreement, announced on September 20, 2024, will provide BRAIN Biotech with significant funding to advance its strategic growth initiatives.
Financial Terms of the Agreement
Under the terms of the agreement, BRAIN Biotech will receive an upfront payment of €18.41 million. Furthermore, the company is eligible for additional regulatory milestone payments of up to €18.42 million, contingent upon the successful progression of deucrictibant through the regulatory approval process. The deal also includes potential long-term sales-related milestone payments, which could reach up to €92.05 million, based on the commercial performance of the drug.
Deucrictibant: A Promising Therapy for Hereditary Angioedema
Deucrictibant, a key asset in BRAIN Biotech’s BioIncubator pipeline, is currently undergoing clinical development by Pharvaris NV (Nasdaq: PHVS). The drug is being investigated for the treatment of Hereditary Angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of severe swelling in various parts of the body, including the face, throat, and abdomen.
Strategic Use of Proceeds
BRAIN Biotech intends to allocate the net proceeds from this royalty monetization deal towards future growth funding and the repayment of existing loans. This financial boost will enable the company to further invest in its research and development programs and strengthen its position in the biotechnology sector.
About BRAIN Biotech AG
BRAIN Biotech AG is a leading industrial biotechnology company specializing in the discovery and development of novel biological solutions. The company leverages its expertise in microbial production and enzyme engineering to create innovative products for various industries, including pharmaceuticals, cosmetics, and food.
